NQO1 * 2 Polymorphism Predicts Overall Survival in Primary MDS Patients

Moudrá, Alena; Minarík, L; Vancurová, M; Hodný, Zdeněk; Bártek, Jiří; Jonášová, Anna

doi:10.1016/s0145-2126(17)30367-3

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Qin et al has shown that PARP-1 V762A may be involved in cancer development at least in some ethnic groups (Asian). 40 In all, our data provide the first demonstration of an influence of the PARP1 V762A polymorphism on the OS and therapeutic response in MDS patients. The PARP1 polymorphism may be a prognostic factor of MDS, confirming previous reports, highlighting a new therapeutic target in the treatment of MDS.…”

Section: Discussionmentioning

confidence: 53%

“…DNA repair‐related genes XPA and XPD were found to be associated with the susceptibility of MDS . In addition, polymorphism in the antioxidant genes NQO1*2 was associated OS in MDS patients . These reports suggest that DNA polymorphism is important for the susceptibility and clinical features of MDS.…”

Section: Discussionmentioning

confidence: 84%

“…38,39 In addition, polymorphism in the antioxidant genes NQO1*2 was associated OS in MDS patients. 40 These reports suggest that DNA polymorphism is important for the susceptibility and clinical features of MDS.…”

Section: Discussionmentioning

confidence: 99%

“…There are some contradictory reports about the association of the PARP1 V762A with tumor risk. The study by Qin et al has shown that PARP‐1 V762A may be involved in cancer development at least in some ethnic groups (Asian) . However, the study by Yu et al found evidence for an association of the PARP‐1 V762A polymorphism with increased risk of cancer among Asians, but decreased risk of cancer among Caucasians .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes

Gotoh

Minato

Saitoh

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objective: Myelodysplastic syndromes (MDS), caused by various genetic mutations in hematopoietic stem cells, are associated with highly variable outcomes. Poly (ADP-ribose) polymerase-1 (PARP1) plays an important role in DNA damage repair and contributes to the progression of several types of cancer. Here, we investigated the impact of PARP1 V762A polymorphism on the susceptibility to and prognosis of MDS.Methods: Samples collected from 105 MDS patients and 202 race-matched healthy controls were subjected to polymerase chain reaction-restriction fragment length polymorphism for genotyping. Results:The allele and genotype frequencies of PARP1 V762A did not differ between MDS patients and the control group. However, MDS patients with the PARP1 V762A non-AA genotype, which is associated with high gene activity, had shorter overall survival rates (P = .01) than those with the AA genotype. Multivariate analysis of overall survival also revealed PARP1 V762A non-AA genotype as a poor prognostic factor (P = .02). When patients were analyzed according to treatment history, the PARP1 V762A non-AA genotype was only associated with poor survival in patients who had received treatment (P = .02).Conclusion: PARP1 V762A polymorphism may be an independent prognostic factor for MDS, and a predictive biomarker for MDS treatment. K E Y W O R D S myelodysplastic syndromes, PARP1, polymorphism | 527 GOTOH eT al.

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes

Gotoh

Minato

Saitoh

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The distribution of the homozygous NQO1*2 in the human population varies between 2% and 20% depending on the ethnic background and is most common in Asian, Mexican Hispanic, and Native American populations . The NQO1*2 genotype is associated with an increased toxicity of benzene and higher risk for several types of cancers including lung, colon, breast, and leukemia . Additionally, an adverse breast cancer outcome has been reported after anthracycline‐based chemotherapy, with a survival rate of 17% for patients with the NQO1*2 genotype compared to 75% for other genotypes .…”

mentioning

confidence: 99%

A small molecule chaperone rescues the stability and activity of a cancer‐associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro

et al. 2019

View full text Add to dashboard Cite

NAD(P)H:quinone oxidoreductase 1 (NQO1) is a human FAD‐dependent enzyme that plays a crucial role in the antioxidant defense system. A naturally occurring single‐nucleotide polymorphism (NQO1*2) in the NQO1 gene leads to an amino acid substitution (P187S), which severely compromises the activity and stability of the enzyme. The NQO1*2 genotype has been linked to a higher risk for several types of cancer and poor survival rate after anthracycline‐based chemotherapy. In this study, we show that a small molecular chaperone (N‐(2‐bromophenyl)pyrrolidine‐1‐sulfonamide) repopulates the native wild‐type conformation. As a consequence of the stabilizing effect, the enzymatic activity of the P187S variant protein is strongly improved in the presence of the molecular chaperone in vitro.

show abstract

NQO1 * 2 Polymorphism Predicts Overall Survival in Primary MDS Patients

Cited by 2 publications

References 0 publications

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes

PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes

A small molecule chaperone rescues the stability and activity of a cancer‐associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro

Contact Info

Product

Resources

About